These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 32413380)

  • 21. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
    Green BD; Irwin N; Duffy NA; Gault VA; O'harte FP; Flatt PR
    Eur J Pharmacol; 2006 Oct; 547(1-3):192-9. PubMed ID: 16945366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).
    Armato JP; DeFronzo RA; Abdul-Ghani M; Ruby RJ
    Lancet Diabetes Endocrinol; 2018 Oct; 6(10):781-789. PubMed ID: 30224284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
    Abbatecola AM; Maggi S; Paolisso G
    Drugs Aging; 2008; 25(11):913-25. PubMed ID: 18947259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.
    Doumas M; Imprialos Κ; Stavropoulos K; Reklou A; Sachinidis A; Athyros VG
    Curr Pharm Des; 2018; 24(17):1879-1886. PubMed ID: 29865997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLUcose COntrol Safety & Efficacy in type 2 DIabetes, a systematic review and NETwork meta-analysis.
    Grenet G; Ribault S; Nguyen GB; Glais F; Metge A; Linet T; Kassai-Koupai B; Cornu C; Bejan-Angoulvant T; Erpeldinger S; Boussageon R; Gouraud A; Bonnet F; Cucherat M; Moulin P; Gueyffier F
    PLoS One; 2019; 14(6):e0217701. PubMed ID: 31237921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
    van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
    Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE; van den Donk M; Wiersma T
    Ned Tijdschr Geneeskd; 2019 Jan; 163():. PubMed ID: 30676706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Mar; 18(3):224-35. PubMed ID: 26500045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.
    Moon HS; Kim MK; Son MH
    Arch Pharm Res; 2011 Jul; 34(7):1041-3. PubMed ID: 21811909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.